Patients who have had a artroscopic investigation of the knee. We want to investigate wheather Ropivacain can be used as a postoperative analgetic drug, when applied ultrasound-guided as a nerve block in the adductor Canal. This could be an alternative method for postoperative analgeisa with less side-effects than i.v.-administrated opioid/neuroaxial blockade. MedDRA version: 12.1 Level: LLT Classification code 10036236 Term: Postoperative pain relief MedDRA version: 12.1 Level: LLT Classific
Conditions
Interventions
Trade Name: Naropin 7.5 mg/mL
Product Name: Ropivacain
Product Code: 17973
Pharmaceutical Form: Injection*
Pharmaceutical form of the placebo: Injection*
Route of administration of the placebo: Perine
Sponsors
Professor Jørgen B. Dahl
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 18-80 years of age Surgery in general anesthesia ASA-group I-III BMI 19-35 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Patients who can not co-operate (e.g. dementia) Patients who do not speak danish Allergic reaktions toward drugs used in the trial Abuse of alcohol/other drugs Patients who can not be mobilised Pregnant women Skin-infektion close to the injection site
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary end point(s): VAS-score 2 hours post surgery, patient standing;Main Objective: Pain/VAS-score, patient standing, 2 hours postoperative;Secondary Objective: Pain/VAS-score at rest at different times during the first 24 hours after surgery Pain/VAS-score standing/when mobilised and after 5 meters walk at different times 24 hours after surgery postoperative opioid-consumption (24 hours) Postoperative nausea/vomiting (24 hours) Postoperative sedation (24 hours) | — |
Countries
Denmark
Outcome results
None listed